Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.205 GBX | -1.62% | -18.29% | -82.01% |
Feb. 22 | Transcript : Shield Therapeutics plc, 2023 Sales/ Trading Statement Call, Feb 22, 2024 | |
Feb. 21 | FTSE 100 takes hit ahead of FOMC minutes | AN |
Sales 2023 * | 12.37M 15.48M | Sales 2024 * | 36.3M 45.4M | Capitalization | 9.58M 11.98M |
---|---|---|---|---|---|
Net income 2023 * | -27M -33.77M | Net income 2024 * | -10M -12.51M | EV / Sales 2023 * | 1 x |
Net Debt 2023 * | 2.82M 3.53M | Net Debt 2024 * | 16.74M 20.94M | EV / Sales 2024 * | 0.72 x |
P/E ratio 2023 * |
-0.31
x | P/E ratio 2024 * |
-0.7
x | Employees | 27 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 43.74% |
Latest transcript on Shield Therapeutics plc
1 day | +2.04% | ||
1 week | -15.25% | ||
Current month | -38.27% | ||
1 month | -37.50% | ||
3 months | -80.00% | ||
6 months | -79.34% | ||
Current year | -81.34% |
Managers | Title | Age | Since |
---|---|---|---|
Gregory Madison
CEO | Chief Executive Officer | 57 | 21-05-31 |
Santosh Shanbhag
DFI | Director of Finance/CFO | 47 | Jan. 15 |
David Childs
COO | Chief Operating Officer | - | 11-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 18-07-25 | |
Director/Board Member | 66 | 16-01-31 | |
Director/Board Member | 57 | 21-05-09 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 1.205 | -1.62% | 3 058 410 |
24-04-25 | 1.225 | -7.55% | 8,963,337 |
24-04-24 | 1.325 | -7.02% | 2,958,047 |
24-04-23 | 1.425 | 0.00% | 700,061 |
24-04-22 | 1.425 | -3.39% | 705,761 |
Delayed Quote London S.E., April 26, 2024 at 04:01 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-81.34% | 11.97M | |
-2.26% | 103B | |
+1.41% | 95.71B | |
+0.82% | 22.02B | |
-17.84% | 20.9B | |
-9.65% | 17.85B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+4.55% | 13.86B | |
+32.11% | 12.04B |
- Stock Market
- Equities
- STX Stock